Endothelial Vehicles as a Novel Anti-Angiogenic Gene Therapy in Cancer of the Prostate
Abstract
Tumor angiogenesis is the common pathophysiological factor of both primary tumors and distant metastases. Therefore, the ablation of the angiogenesis may have a key role to stop tumor progression. In this regard we and others have shown that, when given systemically, normal endothelial progenitors (Eps) circulate and localize into areas of active angiogenesis. In this proposal, we will evaluate the employment of these EPs as cellular vehicles for gene delivery into primary and metastatic carcinoma of the prostate. To this end, we will apply EPs genetically modified ex vivo with a toxin gene for cell-mediated molecular chemotherapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2002
- Accession Number
- ADA412710
Entities
People
- Waleed Arafat
Organizations
- University of Alabama